TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ironwood Pharma ( (IRWD) ) has shared an announcement.
On November 25, 2025, the U.S. Department of Health and Human Services announced the ‘Maximum Fair Price’ for LINZESS® (linaclotide) as part of the Inflation Reduction Act of 2022. The new Medicare net price, effective January 1, 2027, will be $136 for a 30-day supply, aligning with Ironwood Pharmaceuticals’ expectations.
The most recent analyst rating on (IRWD) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Spark’s Take on IRWD Stock
According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.
Ironwood Pharma’s overall stock score is primarily influenced by its financial challenges, including declining revenues and high leverage. While the technical analysis shows bullish momentum, the overbought indicators suggest caution. The valuation is moderate, but the lack of a dividend yield may deter some investors.
To see Spark’s full report on IRWD stock, click here.
More about Ironwood Pharma
Ironwood Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines. Its primary product is LINZESS® (linaclotide), which is used for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Average Trading Volume: 1,945,874
Technical Sentiment Signal: Sell
Current Market Cap: $540.1M
For detailed information about IRWD stock, go to TipRanks’ Stock Analysis page.